Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif.
| Revenue (Most Recent Fiscal Year) | $2.19M |
| Net Income (Most Recent Fiscal Year) | $-24.19M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 7.51 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.11 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1907.18% |
| Net Margin (Trailing 12 Months) | -1919.68% |
| Return on Equity (Trailing 12 Months) | -139.47% |
| Return on Assets (Trailing 12 Months) | -90.88% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.56 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.56 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.14 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.21 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.45 |
| Diluted Earnings per Share (Trailing 12 Months) | $-8.69 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 6.19M |
| Free Float | 5.71M |
| Market Capitalization | $35.33M |
| Average Volume (Last 20 Days) | 0.14M |
| Beta (Past 60 Months) | 2.28 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 60.43% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |